Author

Stefan Schreiber

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Stefan Schreiber  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY
SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Stefan Schreiber  et al.

New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)
New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)

Stefan Schreiber  et al.

LONG-TERM, REAL-WORLD TREATMENT PERSISTENCE AND MUCOSAL HEALING RATES WITH VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
LONG-TERM, REAL-WORLD TREATMENT PERSISTENCE AND MUCOSAL HEALING RATES WITH VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Stefan Schreiber  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

Stefan Schreiber  et al.

ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL
ANALYSIS OF BASELINE CHARACTERISTICS ASSOCIATED WITH CLINICAL RESPONSE TO USTEKINUMAB IV RE-INDUCTION STRATEGY IN PATIENTS WITH CROHN’S DISEASE IN THE POWER TRIAL

Stefan Schreiber  et al.

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Stefan Schreiber  et al.

Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab (Celltrion Healthcare) (Complete Session)
Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab (Celltrion Healthcare) (Complete Session)

Stefan Schreiber  et al.

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Stefan Schreiber  et al.

HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME
HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME

Stefan Schreiber  et al.

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Stefan Schreiber  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Stefan Schreiber  et al.

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

Stefan Schreiber  et al.

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Stefan Schreiber  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Stefan Schreiber  et al.

EARLY RESTORATION OF TRYPTOPHAN DEGRADATION IS ASSOCIATED WITH THERAPY RESPONSE IN ULCERATIVE COLITIS AND DEPENDS ON JAK-STAT SIGNALING
EARLY RESTORATION OF TRYPTOPHAN DEGRADATION IS ASSOCIATED WITH THERAPY RESPONSE IN ULCERATIVE COLITIS AND DEPENDS ON JAK-STAT SIGNALING

Stefan Schreiber  et al.

INDUCTION AND MAINTAINANCE OF STEROID-FREE REMISSION OVER 52 WEEKS WITH VEDOLIZUMAB IN A CASE WITH STEROID-REFRACTORY TYPE 2 AUTOIMMUNE PANCREATITIS
INDUCTION AND MAINTAINANCE OF STEROID-FREE REMISSION OVER 52 WEEKS WITH VEDOLIZUMAB IN A CASE WITH STEROID-REFRACTORY TYPE 2 AUTOIMMUNE PANCREATITIS

Stefan Schreiber  et al.

COMPARISON OF REAL-WORLD TREATMENT PERSISTENCE AND SAFETY OF VEDOLIZUMAB AND ANTI-TUMOR NECROSIS FACTOR-ALPHA TREATMENT IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
COMPARISON OF REAL-WORLD TREATMENT PERSISTENCE AND SAFETY OF VEDOLIZUMAB AND ANTI-TUMOR NECROSIS FACTOR-ALPHA TREATMENT IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Stefan Schreiber  et al.

Item 21 - 40 / 72
1
2
3 4